ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity value MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed (“ArchiMed”), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive ...
Natus Medical Announces First Quarter 2022 Financial Results Q1-2022 Key ResultsRevenue (millions)$119.8 • Total revenue increased 4.2% compared to Q1 2021• Generated $8.9 million in operating cash flowGAAP EPS$0.06 Non-GAAP EPS$0.22 MIDDLETON, Wis., May 05, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months ended March 31, 2022...
Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50 per share in cash Highlights: • Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value• Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, Wis., April 18, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announce...
Natus Medical to Hold 2022 First Quarter Financial Results Conference Call on May 6th PLEASANTON, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th. Natus management will host a conference call on Friday, May 6th at 8:00 a.m. Eastern...
Natus Medical Announces Fourth Quarter 2021 Financial Results Q4-2021 Key ResultsRevenue (millions)$128.7 • Revenue increased 8% compared to Q4 2020• Revenue increased 14% compared to full year 2020• $12.8 million in operating cash flow for Q4 2021• $63.9 million in operating cash flow for the year 2021GAAP EPS$0.05 Non-GAAP EPS$0.47 PLEASANTON, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathw...
Natus Announces Preliminary 2021 Fourth Quarter and Full Year Revenue PLEASANTON, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced preliminary 2021 fourth quarter and full year revenue. The Company expects to report revenue of approximately $127.5 to $128.5 million for the fourth quarter of 2021, and full year 2021 of $472.3 to $473.3 million. “We are p...
Natus to Participate in the 24th Annual Needham Virtual Growth Conference PLEASANTON, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced that Thomas J. Sullivan, President and Chief Executive Officer, and Drew Davies, Executive Vice President and Chief Financial Officer, will be presenting at the 24th Annual Needham Virtual Growth Conference from 2:00 PM ...
Natus Medical to Hold 2021 Fourth Quarter Financial Results Conference Call on February 25th PLEASANTON, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 fourth quarter financial results after the close of the market on Thursday, February 24th. Natus management will host a conference call on Friday, February 25th a...
Natus Medical Announces Executive Transition Thomas J. Sullivan Appointed President & Chief Executive Officer No Change To 4th Quarter Guidance PLEASANTON, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced the appointment of Thomas J. Sullivan as President & Chief Executive Officer effective December 27, 2021 and a focus on long-term growth. Earli...
Natus Medical Announces Third Quarter 2021 Financial Results Q3-2021 Key ResultsRevenue (millions)$113.9 • Revenue increased 11% compared to Q3 2020GAAP EPS$0.16 • Generated $7.1 million in operating cash flowNon-GAAP EPS$0.28 PLEASANTON, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced financial results for the three and nine mont...
Natus Medical Board of Directors Strengthens Governance and Focuses on Growth Establishes Environmental, Social & Governance CommitteeTransitions Quality & Compliance Committee to Innovation & Quality CommitteeNames Thomas J. Sullivan Senior Independent Director PLEASANTON, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company’s Board of Di...
Natus Medical to Hold 2021 Third Quarter Financial Results Conference Call on November 5th PLEASANTON, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 third quarter financial results after the close of the market on Thursday, November 4th. Natus management will host a conference call on Friday, November 5th at 8:0...
Natus Medical Awarded Key New Government Contract Paves the Way for Purchase of Natus Medical Equipment Through United States Government Healthcare System Electronic Catalog PLEASANTON, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, is pleased to announce the award of a 5-year contract to include Natus Patient Monitoring and Capital Equipment (PMCE) in the electroni...
Bryant M. Moore, Ph.D. and Eric J. Guerin Appointed to Natus Board of Directors PLEASANTON, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced the appointments of Bryant M. Moore, Ph.D. and Eric J. Guerin to the Company's Board of Directors. With these appointments, the Natus Board will be expanded to eight members. “We are pleased to welcome Bryant and Er...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Natus Medical Announces Second Quarter 2021 Financial Results Q2-2021 Key ResultsRevenue (millions)$116.0 • Revenue increased 37% compared to Q2 2020• Generated $19.4 million in operating cash flow• GAAP and Non-GAAP EPS increased by $0.36 and $0.42, respectively compared to Q2 2020GAAP EPS$0.10 Non-GAAP EPS$0.29 PLEASANTON, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of al...
First Case Performed Using Natus XactTrode™ Subdural Electrodes Launch to US Market of XactTrodes for Epilepsy Surgical Monitoring PLEASANTON, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, is pleased to announce the completion of the first successfully performed clinical case using Natus’ newly launched XactTrode™ family of platinum subdural electrodes. The Natus Xa...
Natus Medical to Hold 2021 Second Quarter Financial Results Conference Call on August 6th PLEASANTON, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2021 second quarter financial results after the close of the market on Thursday, August 5th. Natus management will host a conference call on Friday, August 6th at 8:00 ...
Natus Chairperson Dr. Barbara Paul Retires; Board Elects Current Board Member Joshua Levine as Chairperson PLEASANTON, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced Dr. Barbara Paul, the Chairperson of the Board of Directors will retire from the Board effective June 30, 2021. The Board has elected independent director Joshua Levine who has served on th...
Natus Medical Announces First Quarter 2021 Financial Results Q1-2021 Key ResultsRevenue (millions)$114.9 • Revenue increased 5% compared to Q1 2020 and in-line with Q1 2019GAAP EPS$0.07 • Generated $24.7 million in operating cash flowNon-GAAP EPS$0.16 • GAAP and Non-GAAP EPS increased by $0.18 and $0.12, respectively compared to Q1 2020 PLEASANTON, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disor...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.